07:00 , Jun 3, 2013 |  BioCentury  |  Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Clinical News

Eladur transdur-bupivacaine: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 263 patients with chronic low back pain showed that 3 Eladur patches administered every 72 hours for 12 weeks missed the primary endpoint of significantly...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Company News

King, Pfizer deal

Pfizer will acquire King in a tender offer of $14.25 per share, or $3.6 billion in cash. The price is a 40% premium to King's close of $10.15 on Oct. 11, before the deal was...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Lux Biosciences management update

Lux Biosciences Inc., Jersey City, N.J.   Business: Ophthalmic   Hired: Dean Mitchell as president and CEO, formerly president and CEO of Alpharma Inc., which was acquired by King Pharmaceuticals Inc. in 2008; he replaces...
00:51 , Jul 2, 2010 |  BC Extra  |  Company News

Lux names Mitchell CEO

Ophthalmic company Lux Biosciences Inc. (Jersey City, N.J.) hired Dean Mitchell as president and CEO. Previously, Mitchell was president and CEO of Alpharma Inc., which King Pharmaceuticals Inc. (NYSE:KG) acquired in 2008. He replaces Ulrich...
07:00 , May 24, 2010 |  BioCentury  |  Finance

What knight?

By Stacy Lawrence Senior Writer OSI Pharmaceuticals Inc. (NASDAQ:OSIP) isn't talking about what happened during its search for buyers, but it looks like the White Knight investors hoped for never showed. Almost two months after it...
07:00 , Apr 12, 2010 |  BC Week In Review  |  Clinical News

Eladur transdur-bupivacaine: Phase IIb started

King began a double-blind, placebo-controlled Phase IIb trial to evaluate 3 Eladur patches administered every 72 hours for 12 weeks in 260 patients. King gained Eladur through its acquisition of Alpharma Inc., which licensed...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

Embeda regulatory update

FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a warning letter to King citing two video news releases promoting Embeda extended-release morphine/naltrexone. The agency said the videos are false or misleading by omitting...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

Embeda regulatory update

King said FDA approved Embeda to manage moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is an extended-release formulation of morphine, an opioid receptor...
00:02 , Aug 14, 2009 |  BC Extra  |  Company News

FDA approves King's Embeda

King Pharmaceuticals Inc. (NYSE:KG) said FDA approved Embeda to manage moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Embeda is an extended-release formulation of morphine,...